NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Onvansertib + Abiraterone:到2030年考慮新藥和市場預測

Onvansertib + Abiraterone - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959714
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
Onvansertib + Abiraterone:到2030年考慮新藥和市場預測 Onvansertib + Abiraterone - Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

第三代三磷酸腺甘抑製劑Onvansertib有望與化學療法和靶向藥物聯合使用。在使用Onvansertib(PCM-075)和醋酸阿維龍酯(Zytiga)進行的II期臨床試驗中,大多數受試者的前列腺特異性抗原(PSA)含量降低。

本報告調查了美國,德國,法國,意大利,西班牙,英國和日本的七個主要國家的Onvansertib + Abiraterone市場,並顯示了2030年的前景。它提供了諸如評估,SWOT分析,競爭對手概況和其他新治療等信息。

調查範圍

  • 全面的產品概述,包括產品描述,作用機理,劑量和給藥方法,研發活動
  • 開發活動的詳細信息,例如法規批准程序的里程碑
  • 美國,歐洲和日本的藥物研發細節
  • 專利信息,包括ONVANSERTIB + ABIRATERONE的截止日期
  • 到2030年ONVAN SERTIB + ABIRATERONE的銷售預測
  • 開發後期有關新治療劑的全面信息(第三階段)
  • 分析師的考慮和SWOT分析

報告重點

  • 將來,由於正在進行的研發和全球醫療費用的增加,前列腺癌藥物的市場格局將發生巨大變化,並且由於市場的擴大,預計會有更多的製藥公司進入該市場。
  • 公司和研究人員正在尋找機會來增強ONVANSERTIB + ABIRATERONE的優勢。目前正在開發的治療方法集中於治療/改善疾病的新方法。
  • 與ONVANS ERTIB + ABIRATERONE競爭的新競爭產品已經出現,並有望在不久的將來對市場產生重大影響。

本報告解決的主要問題

  • 哪個公司在開發ONVANS ERTIB + ABIRATERONE?
  • 使用哪種技術開發ONVANSERTIB + ABIRATERONE?
  • ONVANSERTIB + ABIRATERONE的產品類型,給藥途徑和作用機理是什麼?
  • 臨床試驗的狀態和完成日期是什麼時候?
  • 與ONVANSERTIB + ABIRATERONE的開發相關的主要合作,合併,收購,許可等是什麼?
  • ONVANSERTIB + ABIRATERONE的主要規格是什麼?
  • ONVANSERTIB + ABIRATERONE的預計市場前景是什麼?
  • ONVANSERTIB + ABIRATERONE的歷史和未來前景如何?
  • 您對美國,德國,法國,意大利,西班牙,英國和日本的ONVAN SERTIB + ABIRATERONE的預測如何?
  • 還有哪些其他新產品可用?您如何與這些產品競爭?
  • 在開發後期,目前有哪些新的治療劑?

目錄

第1章藥物概述

  • 產品詳細信息
  • 作用機理
  • 藥物和管理
  • 研發活動
    • 臨床發展
    • 安全性和有效性
  • 其他發展活動

第2章市場評估

  • 7個主要國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 意大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章SWOT分析

第4章分析師的觀點

第5章市場競爭

第6章其他新補救措施

第7章附錄

第8章報表購買選項

目錄
Product Code: DIDM0105

"Onvansertib + Abiraterone- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Onvansertib, a third-generation first-in-class, adenosine triphosphate inhibitor is showing promise when combined with chemotherapies and targeted agents. The combination of onvansertib (PCM-075) with abiraterone acetate (Zytiga) decreased the prostate-specific antigen (PSA) levels in most of the evaluable patients treated in a phase II study (NCT03414034), which used the combination in adult patients with metastatic castration-resistance prostate cancer (mCRPC), according to a press release from onvansertib developer, Trovagene, Inc. The results presented at the European Multidisciplinary Congress on Urological Cancers (EMUC) show that after 3 months of treatment with onvansertib plus abiraterone acetate, 60% of patients has a partial response (PR) or stable disease.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ONVANSERTIB + ABIRATERONE.
  • The report contains forecasted sales for ONVANSERTIB + ABIRATERONE till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
  • The report also features the SWOT analysis with analyst insights and key findings of ONVANSERTIB + ABIRATERONE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ONVANSERTIB + ABIRATERONE Analytical Perspective by DelveInsight

  • In-depth ONVANSERTIB + ABIRATERONE Market Assessment

This report provides a detailed market assessment of ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • ONVANSERTIB + ABIRATERONE Clinical Assessment

The report provides the clinical trials information of ONVANSERTIB + ABIRATERONE covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ONVANSERTIB + ABIRATERONE dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Prostate cancer are giving market competition to ONVANSERTIB + ABIRATERONE and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ONVANSERTIB + ABIRATERONE.
  • Our in-depth analysis of the forecasted sales data of ONVANSERTIB + ABIRATERONE from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ONVANSERTIB + ABIRATERONE.

Key Questions:

  • Which company is developing ONVANSERTIB + ABIRATERONE along with the phase of the clinical study?
  • What is the technology utilized in the development of ONVANSERTIB + ABIRATERONE?
  • What is the product type, route of administration and mechanism of action of ONVANSERTIB + ABIRATERONE?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ONVANSERTIB + ABIRATERONE development?
  • What are the key designations that have been granted to ONVANSERTIB + ABIRATERONE?
  • What is the forecasted market scenario of ONVANSERTIB + ABIRATERONE?
  • What is the history of ONVANSERTIB + ABIRATERONE and what is its future?
  • What is the forecasted sales of ONVANSERTIB + ABIRATERONE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to ONVANSERTIB + ABIRATERONE?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 ONVANSERTIB + ABIRATERONE, Description
  • Table 2 ONVANSERTIB + ABIRATERONE, Clinical Trial Description
  • Table 3 ONVANSERTIB + ABIRATERONE, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of ONVANSERTIB + ABIRATERONE
  • Figure 2 Patent Details, ONVANSERTIB + ABIRATERONE
  • Figure 3 ONVANSERTIB + ABIRATERONE, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 ONVANSERTIB + ABIRATERONE, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 ONVANSERTIB + ABIRATERONE, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 ONVANSERTIB + ABIRATERONE, Japan Market Size from 2020 to 2030 (in Millions USD)